July 01, 2022
Article
A look back at all of the FDA happenings of June 2022.
July 01, 2022
Article
Duvelisib shows possibility of increased risk of death and serious side effects vs other medicines in patients with leukemia and lymphoma.
July 01, 2022
Article
PT886 was granted orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.
June 30, 2022
Article
Botensilimab and balstilimab use in patients with microsatellite stable colorectal cancer showed strong durability and superior efficacy, according to expanded data from the phase 1b C-800 study
June 30, 2022
Article
A phase 1/1b monotherapy clinical trial of RMC-6236 for the treatment of patients with advanced solid tumors driven by a variety of RAS mutations has dosed its first patient.
June 30, 2022
Article
In an interview with Targeted Oncology, Charles J. Schneider, MD, FACP, provided an overview of the treatment landscape for anal carcinoma, and ongoing research.